Lung cancer treatment is advancing at an accelerated pace. However, lung cancer patients still experience some of the worst outcomes compared to other cancer types.
This rapid learning will provide an update on trends in the treatment of lung cancer in Australia and will also focus on the impact of stigma.

Viewing this on mobile? Tell us what you thought. Complete the survey


Become an advocate. Address the stigma.

Resources for health professionals:

  1. Lung Cancer Foundation report: Making lung cancer a fair fight: A blueprint for reform 
  2. Lung cancer in our mob
  3. American Lung Association: Addressing the stigma of lung cancer 
  4. Cancer Australia video: The impact of stigma on people diagnosed with lung cancer

Resources for patients

  1. Cancer Institute NSW: ‘Having lung cancer’ pathway for Aboriginal and Torres Strait Islander people
  2. Lung foundation awareness campaign
  3. Lung foundation support groups
  1. Australian Government 2018, National Cancer Control Indicators: Cancer by stage, Cancer Australia, 22nd October 2018, <>
  2. Global Oncology Trends 2018: Innovation, Expansion and Disruption Institute Report - May 24, 2018
  3. Hall, R.D., Gadgeel, S.M., Garon, E.B., Bria, E., Reck, M., Vida, J., Zhou, H., Raftopoulos, H. and Gandhi, L., 2016. Phase 3 study of platinum-based chemotherapy with or without pembrolizumab for first-line metastatic, nonsquamous non-small cell lung carcinoma (NSCLC): KEYNOTE-189.
  4. Reck, M., Socinski, M.A., Cappuzzo, F., Orlandi, F., Stroyakovskii, D., Nogami, N., Rodríguez-Abreu, D., Moro-Sibilot, D., Thomas, C.A., Barlesi, F. and Finley, G., 2017. LBA1_PR Primary PFS and safety analyses of a randomized phase III study of carboplatin+ paclitaxel+/− bevacizumab, with or without atezolizumab in 1L non-squamous metastatic nsclc (IMPOWER150). Annals of Oncology, 28(suppl_11), pp.mdx760-002.
  5. Horn, L., Reck, M., Mok, T.S.K., Johnson, M., Waterkamp, D., Lam, S., Tang, X., Sandler, A., Lopez-Chavez, A., Giaccone, G. and Liu, S.V., 2016. A Phase III study of atezolizumab with carboplatin plus etoposide in patients with extensive-stage small cell lung cancer (IMpower133). Annals of Oncology, 27(suppl_6).
  6. Delaney, G., Barton, M., Jacob, S. and Jalaludin, B., 2003. A model for decision making for the use of radiotherapy in lung cancer. The lancet oncology, 4(2), pp.120-128.
  7. Vinod, S.K., Simonella, L., Goldsbury, D., Delaney, G.P., Armstrong, B. and O'connell, D.L., 2010. Underutilization of radiotherapy for lung cancer in New South Wales, Australia. Cancer: Interdisciplinary International Journal of the American Cancer Society, 116(3), pp.686-694.
  8. Crino, L., Weder, W., Van Meerbeeck, J. and Felip, E., 2010. Early stage and locally advanced (non-metastatic) non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of oncology, 21, pp.v103-v115.
  9. Videtic, G.M., Donington, J., Giuliani, M., Heinzerling, J., Karas, T.Z., Kelsey, C.R., Lally, B.E., Latzka, K., Lo, S.S., Moghanaki, D. and Movsas, B., 2017. Stereotactic body radiation therapy for early-stage non-small cell lung cancer: Executive Summary of an ASTRO Evidence-Based Guideline. Practical radiation oncology, 7(5), pp.295-301.
  10. Shen, M.J., Hamann, H.A., Thomas, A.J. and Ostroff, J.S., 2016. Association between patient-provider communication and lung cancer stigma. Supportive Care in Cancer, 24(5), pp.2093-2099.
  11. Global Lung Cancer Coalition 2010, Global perceptions of lung cancer, Ipsos MORI, 22nd October 2018 <>
  12. Australian Government 2017, Tobacco position statement, Cancer Australia, 22nd October 2018 <>
  13. Pandeya, N., Wilson, L.F., Bain, C.J., Martin, K.L., Webb, P.M. and Whiteman, D.C., 2015. Cancers in Australia in 2010 attributable to tobacco smoke. Australian and New Zealand journal of public health, 39(5), pp.464-470.


Create your own user feedback survey